This past June, government officials in France and Germany removed the diabetes medication Actos (pioglitazone) from their markets after a study by French researchers discovered a correlation between the drug and an elevated risk of bladder cancer. However, even though the U.S. Food and Drug Administration (FDA) issued a public cautionary statement about the risk and updated the warning information on the product’s label and patient information, Actos and other drugs containing pioglitazone are still available on the U.S. market.
Actos is a leading medicine in a small class of drugs to treat blood sugar levels in Type II diabetes. The FDA said that from January 2010 to October 2010, approximately 2.3 million people received prescriptions for Actos or another drug with pioglitazone. In 2009, Actos sales in the U.S. were around $3.4 billion, as reported by The New York Times. Other drugs it is used in tandem with are Actoplus Met, Actoplus Met XR, and Duetact. The FDA’s warning claims that the Actos bladder cancer risk is highest for individuals using the drug on a long term basis, over a year, and in larger increasing dosages.
An increasing amount of individuals in the U.S. have started a class action lawsuit against the company that makes Actos. Users affected or injured by drug claim that the company did not adequately investigate the drug prior to releasing it on the market and also failed to inform the public of its serious dangers. If you’ve used Actos, or have been harmed by the drug (or any drug containing pioglitazone), contact the Pennsylvania dangerous drug attorneys with Anapol Weiss at (866) 735-2792 for a free case review with an attorney.